Simulations Plus is a health information services business based in the US. Simulations Plus shares (SLP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $27.58 – a decrease of 7.17% over the previous week. Simulations Plus employs 243 staff and has a trailing 12-month revenue of around $70 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $27.58 |
|---|---|
| 52-week range | $27.22 - $51.14 |
| 50-day moving average | $31.31 |
| 200-day moving average | $40.13 |
| Wall St. target price | $52.75 |
| PE ratio | 64.587 |
| Dividend yield | $0.24 (0.75%) |
| Earnings per share (TTM) | $0.46 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $27.62 from 2024-11-19
| 1 week (2024-11-14) | -7.03% |
|---|---|
| 1 month (2024-10-21) | -19.43% |
| 3 months (2024-08-21) | -26.27% |
| 6 months (2024-05-21) | -44.10% |
| 1 year (2023-11-21) | -28.05% |
|---|---|
| 2 years (2022-11-21) | -31.08% |
| 3 years (2021-11-19) | 55.8783 |
| 5 years (2019-11-21) | 34.6033 |
Valuing Simulations Plus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Simulations Plus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Simulations Plus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 65x. In other words, Simulations Plus shares trade at around 65x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Simulations Plus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 9.7712. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Simulations Plus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Simulations Plus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $12.3 million.
The EBITDA is a measure of a Simulations Plus's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $70 million |
|---|---|
| Operating margin TTM | 7.76% |
| Gross profit TTM | $43.1 million |
| Return on assets TTM | 2.85% |
| Return on equity TTM | 5.65% |
| Profit margin | 14.22% |
| Book value | $9.10 |
| Market Capitalization | $596.2 million |
TTM: trailing 12 months
Dividend payout ratio: 36.73% of net profits
Recently Simulations Plus has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Simulations Plus shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Simulations Plus's case, that would currently equate to about $0.24 per share.
While Simulations Plus's payout ratio might seem fairly standard, it's worth remembering that Simulations Plus may be investing much of the rest of its net profits in future growth.
Simulations Plus's most recent dividend payout was on 4 August 2024. The latest dividend was paid out to all shareholders who bought their shares by 28 July 2024 (the "ex-dividend date").
Simulations Plus's shares were split on a 2:1 basis on 1 October 2007 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Simulations Plus shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Simulations Plus shares which in turn could have impacted Simulations Plus's share price.
Over the last 12 months, Simulations Plus's shares have ranged in value from as little as $27.22 up to $51.1426. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Simulations Plus's is 0.709. This would suggest that Simulations Plus's shares are less volatile than average (for this exchange).
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.